From: Prognostic value of ERBB4 expression in patients with triple negative breast cancer
 | Training N = 203 (%) | 5-year disease relapse-free survival (%) | p-value (Log-rank) |
---|---|---|---|
Age (median) | 46.4 ± 10.2 |  |  |
 Range | 23.5-74.1 |  | 0.633 |
  < 40 years | 48 (23.6) | 81.2 |  |
  ≥ 40 years | 155 (76.4) | 86.4 |  |
Histology | Â | Â | 0.507 |
 IDCa | 180 (88.7) | 85.5 |  |
 Others | 23 (11.3) | 82.9 |  |
Stage | Â | Â | <0.001 |
 I | 55 (27.1) | 90.9 |  |
 IIA | 94 (46.3) | 91.5 |  |
 IIB | 33 (16.3) | 78.8 |  |
 IIIA | 13 (6.4) | 67.7 |  |
 IIIB | 0 (0) |  |  |
 IIIC | 8 (3.9) | 25.0 |  |
 Unknown | 0 (0) |  |  |
Nuclear grade | Â | Â | 0.258 |
 1 | 2 (1.0) | 50.0 |  |
 2 | 47 (23.2) | 82.8 |  |
 3 | 145 (71.4) | 86.9 |  |
 Unknown | 9 (4.4) | 77.8 |  |
Histologic grade | Â | Â | 0.704 |
 1 | 3 (1.5) | 100.0 |  |
 2 | 45 (22.2) | 84.4 |  |
 3 | 144 (70.9) | 86.0 |  |
 Unknown | 11 (5.4) | 72.7 |  |
EGFR (median: 7.0) | Â | Â | 0.084 |
 Low | 104 (51.2) | 90.3 |  |
 High | 99 (48.8) | 79.8 |  |
ERBB2 (median: 9.0) | Â | Â | 0.402 |
 Low | 102 (50.2) | 88.2 |  |
 High | 101 (49.8) | 82.1 |  |
ERBB3 (median: 7.2) | Â | Â | 0.106 |
 Low | 102 (50.2) | 90.2 |  |
 High | 101 (49.8) | 80.1 |  |
ERBB4 (median: 1.3) | Â | Â | 0.022 |
 Low | 102 (50.2) | 90.1 |  |
 High | 101 (49.8) | 80.2 |  |
ESR1 (median: 4.4) | Â | Â | 0.689 |
 Low | 102 (50.2) | 84.2 |  |
 High | 101 (49.8) | 86.1 |  |
Adjuvant chemotherapy | Â | Â | 0.001 |
 CMF1 | 86 (42.4) | 90.7 |  |
 FAC2 | 58 (28.6) | 86.0 |  |
 AC3 | 17 (8.4) | 100.0 |  |
 AC –T4 | 41 (20.2) | 65.9 |  |
 Unknown | 1 (0.5) | 100.0 |  |
Adjuvant RTx5 | Â | Â | 0.093 |
 Yes | 130 (64.0) | 83.0 |  |
 No | 73 (36.0) | 89.0 |  |